Biogen Unsuccessful in ICER Attack as Aduhelm Controversy Continues

Biogen has attempted to shield itself from the Institute for Clinical and Economic Review (ICER)’s objections to its Alzheimer’s drug, Aduhelm. ICER is one of many groups finding the drug to be overly expensive and offering no clinical benefit.

“During a panel convened by the California Technology Assessment Forum, Biogen chief medical officer Maha Radhakrishnan vilified the ICER report as “inappropriate” and “fundamentally flawed.” Radhakrishnan particularly objected to ICER’s “blending” of the two Phase III trials in its analysis, leading to its flaws.” Read more here.

(Source: Max Gelman, Endpoints News, 7/15/21)